Figure 4 Time course of the development of physiological changes

Slides:

Advertisements

Similar presentations

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Advertisements

Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Life expectancy at birth in all countries included

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 The US Centers for Disease Control and

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Figure 1 Hypothetical staging model of sporadic Alzheimer disease (AD)

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Cerebrospinal fluid levels of neurofilament light chain

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Overview of risk factors for Parkinson disease dementia

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 The new concept of prodromal RBD

Figure 2 ER stress and proteostasis in neurodegenerative diseases

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Proportion of patients for whom NEDA

Figure 5 Number of AHSCT procedures for

Figure 1 Diagnostic tiers of Parkinson disease as single disease

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Translational research projects in LGMD

Nat. Rev. Neurol. doi: /nrneurol

Figure 6 Imaging methods used to study Parkinson disease

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Algorithm for immunosuppressive treatment

Figure 2 Precision medicine based on a network approach

Figure 1 Principles of therapeutic ultrasound

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Clinical correlates of neurodegeneration in MS

Figure 4 Flow chart of the MDS MSA Study Group aims

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Genetic pleiotropy in ALS

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Evolution of multiple sclerosis

Figure 1 The trajectory of cognitive ageing

Figure 4 Generation of tau seeds and spread of tau pathology

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Challenges for big data applications in cardiovascular care

Figure 2 Diagnostic scheme for MSA

Figure 3 Stroke-related deaths and DALYs by country development status

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Carotid artery inflammation detected using 68Ga-DOTATATE-PET

Figure 6 Combining population-wide and high-risk strategies

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Potential interplay between physiological

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Clinical aspects of LGMD subtypes

Figure 1 The VEGF family of growth factors

Types of biomarkers/biosignatures to be used for cardiovascular disease. Types of biomarkers/biosignatures to be used for cardiovascular disease. There.

Figure 2 Pathophysiological mechanisms in LGMD

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Timing of the effects of deep brain stimulation

Figure 1 A large number of genes are potentially associated with CIPN

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Rett syndrome severity and age at diagnosis by mutation type

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Blood–brain barrier breakdown promotes neurodegeneration

Figure 2 A case of early-onset PSD

Figure 2 Network connections of the hypothalamus

Presentation transcript:

Figure 4 Time course of the development of physiological changes in relation to cognitive and motor changes in neurodegenerative syndromes Figure 4 | Time course of the development of physiological changes in relation to cognitive and motor changes in neurodegenerative syndromes. Physiological markers can develop presymptomatically and early in the disease course, thereby offering the potential to provide accurate, trackable biomarkers of disease. Further research is required to determine precisely when these changes arise in relation to cognitive and physical motor symptoms; the need to determine when changes arise is reflected by dashed lines. Ahmed, R. M. et al. (2018) Physiological changes in neurodegeneration — mechanistic insights and clinical utility Nat. Rev. Neurol. doi:10.1038/nrneurol.2018.23